Arovella Therapeutics
- Short interest
- 0.00%
- 0.00 pp 30d
- as of 16 June 2026
- Reported shorts
- 1.8K
- Shares on issue
- 1.209B
Arovella Therapeutics (ALA) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $800.0KM (source: ASX (Markit))vs $136.0K (FY25)
- ASX (Markit), as at 14 Oct 2026
- NPAT
- −$6.9Mvs −$7.5M (FY25)
- Yahoo Finance, as at 14 Oct 2026
- EPS (diluted)
- −$0.006vs −$0.007 (FY25)
- Yahoo Finance, as at 14 Oct 2026
- Rev YoY
- +488.3%FY
- EPS YoY
- n/aTTM
- ASX (Markit)
Summary of Appendix 4E and Annual Report, 20 Aug 2026
Arovella Therapeutics reported a net loss of $6.9 million for FY2026, a 7.9% improvement from the prior year's $7.5 million loss, with revenue falling to nil from $136,000. No dividend was paid or declared. The company is advancing its lead CAR-iNKT cell therapy ALA-101 into a first-in-human Phase 1 trial, with cash reserves of $14.4 million to fund operations.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 14 Oct 2026
- Gross margin
- n/a
- Operating margin
- −1,401.8%
- Net margin
- −864.5%
- FCF margin
- −868.1%
- ROE
- −40.4%
- ROA
- −37.8%
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- 17.5×
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- $64.1M
- P/E
- n/a
- P/B
- 4.5×
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance and ASX (Markit), as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $800.0KM (source: ASX (Markit)) | $136.0K | $17.0K | $405.9K |
| Gross profit | n/a | $136.0K | $17.0K | $202.4K |
| Operating income | −$11.2M | −$11.2M | −$10.8M | −$9.7M |
| EBITDA | −$11.1M | −$11.1M | −$8.7M | −$9.3M |
| EBIT | −$11.2M | −$11.2M | −$8.7M | −$10.2M |
| Interest expense | n/a | n/a | $8.6K | $20.7K |
| Pretax income | −$6.9M | −$7.5M | −$8.7M | −$10.2M |
| Tax | $0 | $0 | $0 | $0 |
| NPAT | −$6.9M | −$7.5M | −$8.7M | −$10.2M |
| Net interest income | $800.0K | $389.5K | $130.1K | $9.3K |
| EPS basic | −$0.006 | −$0.007 | −$0.009 | −$0.014 |
| EPS diluted | −$0.006 | −$0.007 | −$0.009 | −$0.014 |
| Shares | 1.21B | 1.19B | 1.05B | 849.9M |
- ASX (Markit)
Financial reports
The company's own filings, newest first
- Appendix 4E and Annual ReportAnnual Results20 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report27 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report28 Apr 2026via asx_announcements
- Half Year Report and Appendix 4DHalf Year Results19 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report23 Jan 2026via asx_announcements
- Financial ReportFinancial Report31 Dec 2025via smart_crawler
- Appendix 4GFinancial Report31 Dec 2025via smart_crawler
- Corporate Governance Statement 2025Financial Report31 Dec 2025via smart_crawler
- Financial ReportFinancial Report31 Dec 2025via smart_crawler
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Oct 2025via asx_announcements
Showing 10 of 101 reports